Your browser doesn't support javascript.
Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.
Martinez-Lopez, Antonio; Cuenca-Barrales, Carlos; Montero-Vilchez, Trinidad; Molina-Leyva, Alejandro; Arias-Santiago, Salvador.
  • Martinez-Lopez A; Dermatology Unit, Virgen de las Nieves University Hospital, Granada, Spain; TECe19-Clinical and Translational Dermatology Investigation Group, Instituto Biosanitario, Granada, Spain.
  • Cuenca-Barrales C; TECe19-Clinical and Translational Dermatology Investigation Group, Instituto Biosanitario, Granada, Spain.
  • Montero-Vilchez T; Dermatology Unit, Virgen de las Nieves University Hospital, Granada, Spain.
  • Molina-Leyva A; Dermatology Unit, Virgen de las Nieves University Hospital, Granada, Spain; TECe19-Clinical and Translational Dermatology Investigation Group, Instituto Biosanitario, Granada, Spain. Electronic address: alejandromolinaleyva@gmail.com.
  • Arias-Santiago S; Dermatology Unit, Virgen de las Nieves University Hospital, Granada, Spain; TECe19-Clinical and Translational Dermatology Investigation Group, Instituto Biosanitario, Granada, Spain; Dermatology Department, University of Granada, Granada, Spain.
J Am Acad Dermatol ; 83(6): 1738-1748, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-845104
ABSTRACT
The new coronavirus, severe acute respiratory syndrome coronavirus 2, is associated with a wide variety of cutaneous manifestations. Although new skin manifestations caused by COVID-19 are continuously being described, other cutaneous entities should also be considered in the differential diagnosis, including adverse cutaneous reactions to drugs used in the treatment of COVID-19 infections. The aim of this review is to provide dermatologists with an overview of the cutaneous adverse effects associated with the most frequently prescribed drugs in patients with COVID-19. The skin reactions of antimalarials (chloroquine and hydroxychloroquine), antivirals (lopinavir/ritonavir, ribavirin with or without interferon, oseltamivir, remdesivir, favipiravir, and darunavir), and treatments for complications (imatinib, tocilizumab, anakinra, immunoglobulins, corticosteroids, colchicine and low molecular weight heparins) are analyzed. Information regarding possible skin reactions, their frequency, management, and key points for differential diagnosis are presented.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Drug Eruptions / Coronavirus Infections Type of study: Diagnostic study / Experimental Studies Topics: Long Covid Limits: Humans Language: English Journal: J Am Acad Dermatol Year: 2020 Document Type: Article Affiliation country: J.jaad.2020.08.006

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Drug Eruptions / Coronavirus Infections Type of study: Diagnostic study / Experimental Studies Topics: Long Covid Limits: Humans Language: English Journal: J Am Acad Dermatol Year: 2020 Document Type: Article Affiliation country: J.jaad.2020.08.006